Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
NCT ID: NCT00800332
Last Updated: 2010-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2008-11-30
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CYT003-QbG10
subcutaneous injection
2
CYT003-QbG10
subcutaneous injection
3
Placebo
subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CYT003-QbG10
subcutaneous injection
Placebo
subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Further criteria as defined in the study protocol
Exclusion Criteria
* Clinically relevant perennial allergy/-ies other than house dust mites allergy
* Contraindication to any study test or procedure
* Further criteria as defined in the study protocol
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cytos Biotechnology AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cytos Biotechnology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cytos Investigator Sites
Paide, Tartu, Tallin, Rakvere, , Estonia
Cytos Investigator Sites
Fulda, Dresden, Ulm, Rodgau, Kassel, Eisenach, , Germany
Cytos Investigator Sites
Wiesbaden, Frankfurt/M, Leipzig, Jena, Hamburg, Dulmen, , Germany
Cytos Investigator Sites
N. Faliro, Hiraklion, Athens, , Greece
Cytos Investigator Sites
Riga, Rezekne, , Latvia
Cytos Investigator Sites
Vilnius, Kaunas, Klaipeda, , Lithuania
Cytos Investigator Sites
Galati, Cluj Napoca, Bahia Mare, Brasov, Piesti, , Romania
Cytos Investigator Sites
Targu Mures, Bukarest, Craiova, Iasi, , Romania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, Renner WA, Bachmann MF. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011 Sep;41(9):1305-12. doi: 10.1111/j.1365-2222.2011.03783.x. Epub 2011 Jun 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CYT003-QbG10 09
Identifier Type: -
Identifier Source: org_study_id